Anti-IL-13 monoclonal antibody (Lebrikizumab) from Genentech (Member of the Roche Group, Basel, Switzerland) leads to neutralization of IL-13-related pharmacodynamic biomarkers, although its effect on significant reduction in asthma exacerbations was not consistent, especially in biomarker-high patients [16, 17]. The gene discussed is IL13; the disease is asthma.